Mallinckrodt C - Search Results

1

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.

Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A. Budd Haeberlein S, et al. Among authors: mallinckrodt c. J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30. J Prev Alzheimers Dis. 2022. PMID: 35542991 Clinical Trial.

2

Points to consider for analyzing efficacy outcomes in long-term extension clinical trials.

Ratitch B, Lipkovich I, Erickson JS, Zhang L, Mallinckrodt CH. Ratitch B, et al. Pharm Stat. 2018 Nov;17(6):685-700. doi: 10.1002/pst.1888. Epub 2018 Jul 26. Pharm Stat. 2018. PMID: 30051580

3

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).

Langley RG, Papp K, Gooderham M, Zhang L, Mallinckrodt C, Agada N, Blauvelt A, Foley P, Polzer P; of the IXORA-P Investigators. Langley RG, et al. Among authors: mallinckrodt c. Br J Dermatol. 2018 Jun;178(6):1315-1323. doi: 10.1111/bjd.16426. Epub 2018 May 15. Br J Dermatol. 2018. PMID: 29405255 Clinical Trial.

4

Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice.

Merola JF, Amato DA, See K, Burge R, Mallinckrodt C, Ojeh CK, Gottlieb A. Merola JF, et al. Among authors: mallinckrodt c. J Invest Dermatol. 2018 Sep;138(9):1955-1961. doi: 10.1016/j.jid.2018.01.041. Epub 2018 Mar 22. J Invest Dermatol. 2018. PMID: 29577919 Free article. Clinical Trial.

5

To adjust or not to adjust for baseline when analyzing repeated binary responses? The case of complete data when treatment comparison at study end is of interest.

Jiang H, Kulkarni PM, Mallinckrodt CH, Shurzinske L, Molenberghs G, Lipkovich I. Jiang H, et al. Pharm Stat. 2015 May-Jun;14(3):262-71. doi: 10.1002/pst.1682. Epub 2015 Apr 10. Pharm Stat. 2015. PMID: 25866149

6

Using principal stratification in analysis of clinical trials.

Lipkovich I, Ratitch B, Qu Y, Zhang X, Shan M, Mallinckrodt C. Lipkovich I, et al. Among authors: mallinckrodt c. Stat Med. 2022 Aug 30;41(19):3837-3877. doi: 10.1002/sim.9439. Epub 2022 Jun 13. Stat Med. 2022. PMID: 35851717

7

A structured approach to choosing estimands and estimators in longitudinal clinical trials.

Mallinckrodt CH, Lin Q, Lipkovich I, Molenberghs G. Mallinckrodt CH, et al. Pharm Stat. 2012 Nov-Dec;11(6):456-61. doi: 10.1002/pst.1536. Epub 2012 Sep 10. Pharm Stat. 2012. PMID: 22962024

8

The challenges of evaluating dose response in flexible-dose trials using marginal structural models.

Lipkovich I, Mallinckrodt CH, Faries DE. Lipkovich I, et al. Pharm Stat. 2012 Nov-Dec;11(6):485-93. doi: 10.1002/pst.1540. Epub 2012 Oct 12. Pharm Stat. 2012. PMID: 23060290

9

Comparison of several multiple imputation strategies for repeated measures analysis of clinical scales: to truncate or not to?

Lipkovich I, Kadziola Z, Xu L, Sugihara T, Mallinckrodt CH. Lipkovich I, et al. J Biopharm Stat. 2014;24(4):924-43. doi: 10.1080/10543406.2014.901344. J Biopharm Stat. 2014. PMID: 24697735

10

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.

Ratitch B, Bell J, Mallinckrodt C, Bartlett JW, Goel N, Molenberghs G, O'Kelly M, Singh P, Lipkovich I. Ratitch B, et al. Among authors: mallinckrodt c. Ther Innov Regul Sci. 2020 Mar;54(2):324-341. doi: 10.1007/s43441-019-00061-x. Epub 2020 Jan 4. Ther Innov Regul Sci. 2020. PMID: 32072573

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters